Charité-Universitätsmedizin Berlin, Germany.
Johannes Gutenberg-University Mainz, Germany.
Sex Abuse. 2021 Jun;33(4):475-500. doi: 10.1177/1079063220910723. Epub 2020 Mar 13.
For a particular subgroup of individuals with severe paraphilic disorders and a high risk of sexual recidivism, the combination of sex drive-reducing medications and psychotherapy is a promising treatment approach. The present quasi-experimental study aims at comparing differences in clinical characteristics and dynamic risk factors between persons receiving (+TLM, = 38) versus not receiving (-TLM, = 22) testosterone-lowering medications (TLMs). Individuals receiving TLM were more frequently diagnosed with paraphilic disorders. Neither the criminal history nor average risk scores differed between the two groups. In the +TLM, Stable-2007 scores showed a stronger decrease after TLM treatment was started. This accounted especially for the general and sexual self-regulation subscales. Individual variations in risk, however, were not predicted by TLM but were significantly related to treatment duration and Psychopathy Checklist-Revised (PCL-R) Factor I. Paraphilic patients with problems in self-regulatory abilities seem to profit most from pharmacological sex drive-reducing treatment. Furthermore, therapists seem to underestimate deviant sexual fantasies in medicated patients.
对于某些严重的性癖障碍和高性犯罪复发风险的特定亚组人群,降低性欲药物和心理治疗的结合是一种有前途的治疗方法。本准实验研究旨在比较接受(+TLM,n=38)和未接受(-TLM,n=22)睾丸素降低药物(TLM)治疗的个体之间的临床特征和动态风险因素的差异。接受 TLM 的个体更频繁地被诊断为性癖障碍。两组的犯罪史或平均风险评分均无差异。在+TLM 中,稳定-2007 评分在开始 TLM 治疗后下降更为明显。这尤其适用于一般和性自我调节子量表。然而,风险的个体差异不受 TLM 预测,而是与治疗持续时间和精神病理检查表修订版(PCL-R)因子 I 显著相关。在自我调节能力方面存在问题的性癖障碍患者似乎从药物降低性欲治疗中获益最多。此外,治疗师似乎低估了接受药物治疗的患者的异常性幻想。